NASDAQ:WVE

Wave Life Sciences - WVE Stock Forecast, Price & News

$3.78

+0.13 (+3.56%)

(As of 09/28/2022 12:00 AM ET)

Add

Compare

Today's Range: $3.66
▼
$4.13
50-Day Range: $2.37
▼
$3.92
52-Week Range: $1.16
▼
$5.53

Volume: 410,771 shs
Average Volume: 434,250 shs
Market Capitalization: $328.18 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.00

Wave Life Sciences MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 111.6% Upside
$8.00 Price Target
Short Interest: Healthy
1.72% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.67
Upright™ Environmental Score
News Sentiment: 0.40
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.24) to ($1.68) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.62 out of 5 stars

Medical Sector

120th out of 1,096 stocks

Pharmaceutical Preparations Industry

42nd out of 548 stocks

3.5

Analyst's Opinion

Consensus Rating
Wave Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.00, Wave Life Sciences has a forecasted upside of 111.6% from its current price of $3.78.
Amount of Analyst Coverage
Wave Life Sciences has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
1.72% of the outstanding shares of Wave Life Sciences have been sold short.
Short Interest Ratio / Days to Cover
Wave Life Sciences has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Wave Life Sciences has recently decreased by 0.67%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Wave Life Sciences does not currently pay a dividend.
Dividend Growth
Wave Life Sciences does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Wave Life Sciences has received a 73.43% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Preclinical research services for physical health", "Basic medical research services", and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Wave Life Sciences is -0.67.

2.4

News and Social Media Coverage

News Sentiment
Wave Life Sciences has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Wave Life Sciences this week, compared to 1 article on an average week.
Search Interest
Only 7 people have searched for WVE on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.
MarketBeat Follows
1 people have added Wave Life Sciences to their MarketBeat watchlist in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Wave Life Sciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
32.20% of the stock of Wave Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
89.28% of the stock of Wave Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Wave Life Sciences are expected to grow in the coming year, from ($2.24) to ($1.68) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Wave Life Sciences is -1.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Wave Life Sciences is -1.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Wave Life Sciences has a P/B Ratio of 6.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Wave Life Sciences (NASDAQ:WVE) Stock

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.

Receive WVE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Wave Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

WVE Stock News Headlines

September 28, 2022 | finance.yahoo.com

Wave Life Sciences Highlights Therapeutic Potential for WVE-006 for Alpha-1 Antitrypsin Deficiency and Progress Bringing RNA Editing to the Clinic During Analyst and Investor Event

September 27, 2022 | finance.yahoo.com

Wave Life Sciences to Present at Chardan’s 6th Annual Genetic Medicines Conference

September 23, 2022 | nasdaq.com

Investors in Wave Life Sciences (NASDAQ:WVE) from five years ago are still down 82%, even after 17% gain this past week

September 20, 2022 | seekingalpha.com

Wave Life stock rises as WVE-003 shows promise in interim data of Huntington's disease trial

September 20, 2022 | finance.yahoo.com

Wave Life Sciences Announces Positive Update from Phase 1b/2a SELECT-HD Trial with Initial Results Indicating Allele-Selective Target Engagement with WVE-003 in Huntington’s Disease

September 20, 2022 | finance.yahoo.com

Wave Life Sciences Touts Positive Update From Its Lead Huntington's Program

September 18, 2022 | benzinga.com

"Towards the Clinic: Spotlight on RNA Editing for AATD"

September 16, 2022 | finance.yahoo.com

Wave Life Sciences to Host Analyst and Investor Virtual Event, “Towards the Clinic: Spotlight on RNA Editing for AATD,” on September 28, 2022

September 16, 2022 | msn.com

25 Years Later, Wave Race 64's Water Is Still Undefeated

August 13, 2022 | finance.yahoo.com

News Flash: 7 Analysts Think Wave Life Sciences Ltd. (NASDAQ:WVE) Earnings Are Under Threat

August 3, 2022 | finance.yahoo.com

Mirati (MRTX) Reports Q2 Loss, Tops Revenue Estimates

July 28, 2022 | finance.yahoo.com

Wave Life Sciences to Webcast Conference Call of Second Quarter 2022 Financial Results on August 11, 2022

July 27, 2022 | nasdaq.com

What Is The Ownership Structure Like For Wave Life Sciences Ltd. (NASDAQ:WVE)?

July 20, 2022 | finance.yahoo.com

Investors three-year losses grow to 82% as the stock sheds US$39m this past week

June 22, 2022 | markets.businessinsider.com

U.S. Stocks Turn Higher; Athira Pharma Shares Plummet

June 22, 2022 | seekingalpha.com

Ra Capital Management raises passive stake in Wave Life Sciences

June 17, 2022 | msn.com

WAVE Life Sciences's Return On Capital Employed Insights

June 14, 2022 | seekingalpha.com

Wave Life Sciences to raise $70M in stock offering

June 14, 2022 | finance.yahoo.com

Wave Life Sciences Announces Pricing of $70.0 Million Underwritten Offering

May 25, 2022 | finance.yahoo.com

Wave Life Sciences to Present at the 2022 Jefferies Healthcare Conference

May 13, 2022 | seekingalpha.com

Wave Life Sciences slips as H.C. Wainwright lowers target

May 13, 2022 | finance.yahoo.com

Ahead Of Upcoming Data On Three Programs, Analysts Remain On Sidelines For Wave Life Sciences

May 12, 2022 | finance.yahoo.com

Wave Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update

May 11, 2022 | benzinga.com

WAVE Life Sciences Earnings Preview

May 11, 2022 | seekingalpha.com

Wave Life Sciences Q1 2022 Earnings Preview

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive WVE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Wave Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

WVE Company Calendar

Last Earnings: 8/11/2022
Today: 9/28/2022
Next Earnings (Estimated): 11/09/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:WVE
CUSIP: N/A
CIK: 1631574
Web: www.wavelifesciences.com
Phone: (656) 236-3388
Fax: 617-949-2901
Employees: 235
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $8.00
High Stock Price Forecast: $8.00
Low Stock Price Forecast: $8.00
Forecasted Upside/Downside: +111.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.97)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-122,250,000.00
Net Margins: -297.98%
Pretax Margin: -298.49%
Return on Equity: -515.04%
Return on Assets: -60.96%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.50
Quick Ratio: 2.50

Sales & Book Value

Annual Sales: $40.96 million
Price / Sales: 8.01
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.55 per share
Price / Book: 6.87

Miscellaneous

Outstanding Shares: 86,820,000
Free Float: 58,864,000
Market Cap: $328.18 million
Optionable: Optionable
Beta: -0.55

Key Executives

Dr. Paul B. Bolno M.B.A. (Age 48)
M.D., MBA, Pres, CEO & Director
Comp: $994.61k

Dr. Chandra Vargeese Ph.D. (Age 61)
Chief Technology Officer
Comp: $656.06k

Dr. Michael A. Panzara M.D. (Age 55)
M.P.H., MPH, Chief Medical Officer and Head of Therapeutics Discovery & Devel.
Comp: $692.94k

Mr. Kyle B. Moran CFA (Age 51)
CFO & Principal Accounting Officer

Kate Rausch
Head of Investor Relations

Ms. Linda Rockett J.D.
Gen. Counsel

Ms. Anne-Marie Li-Kwai-Cheung
Sr. VP of Regulatory Affairs, Compliance & Policy

Dr. Christopher Francis Ph.D. (Age 44)
Sr. VP of Corp. Devel. & Head of Emerging Areas

Mr. Jonathan Rosin
Chief HR Officer

Dr. Sridhar Vaddeboina Ph.D.
Sr. VP of Chemistry, Manufacturing & Controls

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

WVE Stock - Frequently Asked Questions

Should I buy or sell Wave Life Sciences stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Wave Life Sciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" WVE shares.
View WVE analyst ratings or view top-rated stocks.
What is Wave Life Sciences' stock price forecast for 2022?: 1 brokers have issued 12-month target prices for Wave Life Sciences' stock. Their WVE share price forecasts range from $8.00 to $8.00. On average, they anticipate the company's share price to reach $8.00 in the next year. This suggests a possible upside of 111.6% from the stock's current price.
View analysts price targets for WVE or view top-rated stocks among Wall Street analysts.
How have WVE shares performed in 2022?: Wave Life Sciences' stock was trading at $3.14 at the start of the year. Since then, WVE stock has increased by 20.4% and is now trading at $3.78.
View the best growth stocks for 2022 here.
When is Wave Life Sciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our WVE earnings forecast.
How were Wave Life Sciences' earnings last quarter?: Wave Life Sciences Ltd. (NASDAQ:WVE) posted its quarterly earnings data on Thursday, August, 11th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.56) by $0.06. The company earned $0.38 million during the quarter, compared to analysts' expectations of $3.25 million. Wave Life Sciences had a negative trailing twelve-month return on equity of 515.04% and a negative net margin of 297.98%.
What is Paul Bolno, M.D., MBA's approval rating as Wave Life Sciences' CEO?: 17 employees have rated Wave Life Sciences Chief Executive Officer Paul Bolno, M.D., MBA on Glassdoor.com. Paul Bolno, M.D., MBA has an approval rating of 92% among the company's employees. This puts Paul Bolno, M.D., MBA in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Wave Life Sciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Wave Life Sciences investors own include Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), Aduro Biotech (ADRO), Cidara Therapeutics (CDTX), CRISPR Therapeutics (CRSP) and ImmunoGen (IMGN).
What is Wave Life Sciences' stock symbol?: Wave Life Sciences trades on the NASDAQ under the ticker symbol "WVE."
How do I buy shares of Wave Life Sciences?: Shares of WVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Wave Life Sciences' stock price today?: One share of WVE stock can currently be purchased for approximately $3.78.
How much money does Wave Life Sciences make?: Wave Life Sciences (NASDAQ:WVE) has a market capitalization of $328.18 million and generates $40.96 million in revenue each year. The company earns $-122,250,000.00 in net income (profit) each year or ($1.97) on an earnings per share basis.
How many employees does Wave Life Sciences have?: The company employs 235 workers across the globe.
How can I contact Wave Life Sciences?: Wave Life Sciences' mailing address is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. The official website for the company is www.wavelifesciences.com. The company can be reached via phone at (656) 236-3388, via email at krausch@wavelifesci.com, or via fax at 617-949-2901.

This page (NASDAQ:WVE) was last updated on 9/29/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Wave Life Sciences - WVE Stock Forecast, Price & News

Wave Life Sciences MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows